Navigation Links
Study Suggests a Possible Way to Offset Chemobrain Memory Loss
Date:9/5/2008

MORGANTOWN, W.Va., Sept. 5 /PRNewswire-USNewswire/ -- Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University, researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce.

In the WVU researchers' study, published in the September issue of the journal Metabolic Brain Disease, rats were given the commonly used chemotherapy drugs adriamycin and cyclophosphamide. When on the drugs, rats trained to prefer a light room to a dark room forgot their training.

"When animals are treated with chemotherapy drugs, they lose memory," said Gregory Konat, Ph.D., professor of neurobiology and anatomy at WVU. "When we add NAC during treatment, they don't lose memory."

Chosen for its antioxidant properties, NAC is a modified form of the dietary amino acid cysteine.

Jame Abraham, M.D., director of the Comprehensive Breast Cancer Program at WVU's Mary Babb Randolph Cancer Center, said as "chemobrain" entered the national lexicon, many patients expressed frustration about doctors not taking the complaints seriously.

"In the past, there was a lot of ignorance among doctors about chemo-induced cognitive problems," Dr. Abraham said. "In some patients, problems can persist for up to two years."

The WVU authors say as many as 40 percent of cancer patients undergoing chemotherapy complain of symptoms such as severe memory and attention deficits. Previously, scientists suspected the cancer, rather than chemo drugs, might be the cause.

Earlier this year, Dr. Abraham's team of researchers used MRI scans to document the extent of changes to the brain in women who received chemotherapy for breast cancer. Now the connection between drugs and memory loss is clear, and a potential remedy is suggested as well.

"At this point, we have no evidence to say that NAC is safe in patients who are getting chemotherapy," Abraham said. "We need more studies to confirm the role of NAC in patients."

In addition to the Department of Neurobiology and Anatomy, researchers from WVU's Mary Babb Randolph Cancer Center and Department of Behavioral Medicine and Psychiatry collaborated on the study.

The study was funded as part of a $275,000 grant over three years from the U.S. Department of Defense. Abraham is principle investigator on the studies.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE West Virginia University Health Sciences Center
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytopia Commences Second Phase II Study in Brain Cancer
2. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. CDC Misses Target With Flawed MMR/Autism Study
5. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
6. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch
8. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
9. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
10. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
11. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Feb. 12, 2016   National Community Pharmacists Association ... MBA issued the following statement today in response to ... the Centers for Medicare & Medicaid Services (CMS) ... beneficiary advocates and others: patient advocacy organizations ... still reviewing the full CMS analysis. Our initial reaction ...
(Date:2/12/2016)... , Feb. 12, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO ) is pleased to ... Account Management and Payor Strategies effective Jan. 23, 2016. ... ... ... Diplomat Specialty Pharmacy ...
(Date:2/12/2016)... MONTREAL , February 12, 2016 ... sofern nicht anders vermerkt)   ... Unternehmens http://www.telestatherapeutics.com abrufbar.    ... Website des Unternehmens http://www.telestatherapeutics.com ... Inc. (TSX:TST; PNK:BNHLF) veröffentlichte heute seinen Konzernabschluss ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... , ... The producers of Enterprises TV are pleased to present ... world of instantaneous consumption proves very convenient for businesses. With new technologies constantly becoming ... which pollutes our air, water, and soil. It can also threaten the lives of ...
(Date:2/13/2016)... ... 13, 2016 , ... DDi , a Makro company, ... for its expertise in eClinical Solutions. DDi has built its solution competency with ... of global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... to funding innovative lymphoma research and serving the lymphoma community through a comprehensive ... members of South Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker ... Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and ... hydrated before the big event. The invitation-only gifting suite, held this year at the ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... Fisher House ... Vegas Mayor John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy ... at the VA Southern Nevada Healthcare System. This will be the first Fisher ...
Breaking Medicine News(10 mins):